BRCA2 (BRCA2 DNA repair associated; HGNC:1101, NCBI Gene 675) is the gene on chromosome 13q13.1 encoding the 3,418-amino-acid protein that physically delivers RAD51 recombinase to resected DNA double-strand breaks — the homologous-recombination pathway's delivery truck, acting downstream of BRCA1 in the same repair pipeline. Germline mutations cause hereditary breast and ovarian cancer syndrome (breast-cancer risk to ~69% by age 80), with added pancreatic and prostate risk; like BRCA1 loss, BRCA2-deficient tumors are PARP-inhibitor sensitive.
Approved Symbol
BRCA2 (HGNC:1101)
Chromosomal Locus
13q13.1
Encoded Product
BRCA2 — a 384-kDa nuclear protein (3,418 aa) with eight BRC repeats
Hereditary breast/ovarian/pancreatic cancer; PARP-inhibitor and platinum sensitivity
Gene Structure & Expression
Genomic organization: 27 exons; exon 11 is enormous (~5 kb), encoding the central BRC repeats that bind RAD51 — one of the largest coding exons in the genome, and a mutation target.
Expression: Induced in S phase with the repair machinery; the protein shuttles to nuclear foci at damage sites, and its C-terminal RAD51-binding site (Ser3291-phosphorylation regulated) coordinates filament assembly with cell-cycle position.
Molecular Function & Pathways
RAD51 delivery: The eight BRC repeats hold RAD51 monomers (inhibiting their self-assembly) and release them as filaments on the single-stranded DNA at resected breaks — BRCA2 is the dedicated loader that homologous recombination cannot proceed without; the DNA-binding and DSS1-associated domains complete the apparatus.
Fanconi anemia overlap: BRCA2 is FANCD1 — biallelic mutations give a Fanconi-anemia subtype, the recessive face of a dominant cancer gene.
Clinical & Therapeutic Significance
Cancer genetics: Germline variants confer up to 69% lifetime breast-cancer and 17–20% ovarian-cancer risk (later average onset than BRCA1); pancreatic (~5–10%) and prostate risk elevated; the 6174delT founder mutation in Ashkenazi populations.
Therapeutics: PARP inhibitors and platinum both exploit the homologous-recombination defect; unlike BRCA1-mutant tumors, BRCA2-mutant breast cancers often retain estrogen-receptor expression — endocrine therapy's added role.